A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S T | U | V | W | X | Y | Z

Articles are indexed by drug names, trade names and disease terms. Bold entries refer to major references.

Key Word / Drug Name
Issue #: Page #

A
ABSSSI 1:12; 2:7
acne scars 5:2,3,5,6
acne 2:7; 6:10
acute bacterial skin and skin structure infections 1:12; 2:7
Aczone® 6:10
adalimumab 1:12; 2:8,9; 5:14
adjuvant therapy (melanoma) 1:10-11; 2:7
aesthetic 5:1-6
afamelanotide 6:10
aging skin 1:12; 2:8,10
Aklief® 6:10
aluminum chloride 1:1-3
androgenic alopecia 5:1-6
anthraquinone 3:7-9
antibiotic 1:12; 2:7; 6:10
anticholinergic 1:1-3; 2:1-3,8
antiperspirants 1:1-3
antiviral 2:8
apremilast 5:14
ASN002 2:10
atopic dermatitis 2:4-6,8,10; 3:10; 5:14; 6:6,10
autologous fat grafting 5:1,3,4,6
axillary hyperhidrosis 1:1-7; 2:1-3

B
Behcet’s disease 5:14
belimumab 4:8
bempegaldesleukin 5:14
Benlysta® 4:8
betamethasone 5:14
binimetinib 2:7
biosimilar 1:12; 2:8
biotin 5:11
blistering 3:7-9; 6:6
body contouring 5:14
botulinum toxin 1:3-4; 2:8,10
B-Raf proto-oncogene (BRAF) 1:8-11; 2:7
brentuximab vedotin 2:7
brodalumab 2:9; 4:1-4
Bryhali™ 1:12; 2:9

C
calcipotriene 5:14
camouflaging agents 3:4
cellular grafting 3:4
cemiplimab-rwlc 2:7
certolizumab pegol 2:9
checkpoint inhibitor 1:8-11; 2:7,8,9
chronic urticaria 6:5-6
combination immunotherapy 1:10
CoolTone™ 5:14
corticosteroid 4:8; 5:14
Cosentyx® 2:9
crisaborole 2:4-6,8
CSCC 2:7
CTCL 2:7,8
CTLA-4 1:8-11
cutaneous lupus erythematosus 6:6
cutaneous sarcoidosis 6:6
cutaneous squamous cell carcinoma 2:7
cutaneous T-cell lymphoma 2:7
cytotoxic T-lymphocyte-associated protein 4 1:8-11

D
dabrafenib 2:7
delafloxacin 1:12; 2:7
dapsone 6:10
depigmentation therapies 3:4-5
dermal filler 1:12; 2:8; 5:5-6; 6:10
diacerein 3:7-9
DRM04 1:1-3; 2:1-3
drug interactions 6:7
Duobrii™ 4:8
dupilumab 3:10; 5:14
Dupixent® 3:10; 5:14

E
eczema 2:4-6,8,10; 3:10; 5:14; 6:6,10
Enbrel® 4:8
encorafenib 2:7
Enstilar® 5:14
eon™ FR 5:14
epidermolysis bullosa simplex 3:7-9
erythropoietic protoporphyria (EPP) 6:10
etanercept 4:8
Eticovo™ 4:8
Eucrisa® 2:4-6,8

F
Fabry disease 2:8
facial rejuvenation 5:1-3,5-6
fat injections 5:3-6
focused ultrasound 1:3-5
fractional laser resurfacing 5:2-3,5

G
Galafold™ 2:8
Gardasil®9 2:8
glycopyrronium tosylate 1:1-3; 2:1-3,8
graft-versus-host disease (GVHD) 4:8
granulomatosis with polyangiitis (GPA) 6:10
guselkumab 3:10

H
Hadlima™ 2:8,9; 5:14
hair restoration 5:1-4
hair 5:7-13
halobetasol propionate 1:12; 2:9; 4:8
hepatotoxicity 6:6-7
hereditary angioedema 2:8
herpes zoster 3:5-7
hidradenitis suppurativa 2:8,9
human papillomavirus (HPV) 2:8
Humira® 1:12; 2:8,9; 5:14
hyaluronic acid dermal filler 1:12; 2:8; 6:10
hyperhidrosis 1:1-7; 2:1-3,8
Hyrimoz™ 1:12; 2:9

I
Ilumya™ 1:12; 2:9; 6:1-4
immunotherapy 1:8-11; 2:10
interleukin-13 (IL-13) 3:10
interleukin-17 (IL-17) 2:9; 4:1-4
interleukin-23 (IL-23) 1:12; 2:9; 3:10; 4:8; 6:1-4
interleukin-4 (IL-4) 3:10
iontophoresis 1:2-4
ipilimumab 1:8-11; 2:7
ixekizumab 2:9

J
Jakafi® 4:8
Janus kinase (JAK) inhibitors 4:8
Jeuveau™ 2:10
Juvederm® 6:10
Jynneos™ 6:10

K
Keytruda® 1:8-11,12; 2:8,10; 3:10

L
lanadelumab-flyo 2:8
laser therapy 1:3-5; 5:2-3,5; 5:14
lidocaine 2:9,10
localized scleroderma 6:6
lupus 4:8; 6:6

M
magnetic muscle stimulation 5:14
MEK inhibitor 1:8-11; 2:7; 4:8
Mekinist® 2:7
melanocortin 1 receptor (MC1R) 6:10
melanoma 1:8-11; 2:7; 3:10; 5:14
melatonin 5:11
mental health 4:1-4
merkel cell carcinoma 1:12; 2:8,10
methicillin resistant Staphylococcus aureus 1:12
methotrexate 6:5-8
microneedling 5:2-3,5
microwave thermolysis 1:3-4
migalastat 2:8
mitogen-activated protein kinase
kinase inhibitor 1:8-11; 2:7
mogamulizumab-kpkc 2:8
monoclonal antibody 1:12; 2:8,9; 3:10; 6:1-4
MRSA 1:12
mycosis fungoides 2:8; 6:6

N
nail 5:7-11
neurofibromatosis 4:8
niacinamide 5:11
nivolumab 1:8-11; 5:14
NKTR-214 5:14
Nuceiva® 2:8
Nuzyra™ 1:12; 2:7

O
omadacycline 1:12; 2:7
Opdivo® 1:8-11; 5:14
Otezla® 5:12

P
PD-0325901 4:8
pembrolizumab 1:8-11,12; 2:8,10; 3:10
pemphigus vulgaris 2:8
phosphodiesterase-4 inhibitor (PDE-4) 2:4-6,8; 5:14
phototherapy 3:3
phototoxicity 6:10
platelet-rich plasma (PRP) 5:1-6
Pliaglis® 2:10
post-herpetic neuralgia (PHN) 2:9; 4:5
Poteligeo® 2:8
PPIES 5:7-13
prabotulinumtoxinA 2:8,10
prebiotics 5:11
probiotics 5:11
programmed cell death-ligand 1 (PD-L1) 1:8-11; 2:7,8,10; 3:10; 5:14
protein replacement therapy (PTR-01) 4:8
psoriasis 1:12; 2:8,9; 3:10; 4:8; 5:14; 6:1-4,5
psoriatic arthritis 1:12; 2:8,9; 4:8

Q
Qbrexza™ 1:1-3; 2:1-3,8

R
rash 4:5-7
recessive dystrophic epidermolysis bullosa 4:8
recombinant subunit vaccine 4:5-7
Restylane® Lyft 1:12; 2:8
retinoic acid receptor 6:10
retinoid 4:8; 6:10
rhein prodrug 3:7-9
rhytids 5:1-3,5-6
risankizumab 3:10; 4:8
Rituxan® 2:8; 6:10
rituximab 2:8; 6:10
ruxolitinib 4:8

S
sarcoidosis 6:6
sarecycline hydrochloride 2:7
scalp psoriasis 2:9
scars 5:1-3,5
Scenesse® 6:10
scleroderma 6:6
secukinumab 2:9
Sézary syndrome 2:8
shingles 2:9; 4:5-7
Shingrix® 4:5-7
Siliq™ 2:9; 4:1-4
Skyrizi™ 3:10; 4:8
smallpox 2:8; 6:10
striae distensae 5:3,6
suicidal ideation 4:1-4
supplements 5:7-11
sweat 1:1-7; 2:1-3,8
sympathectomy 1:3-6
synbiotics 5:11
systemic lupus erythematosus 4:8

T
Taclonex® 5:14
Tafinlar® 2:7
Takhzyro™ 2:8
Talz® 2:9
tazarotene 4:8
tecovirimat 2:8
tetracaine 2:10
thermolysis 1:3-4
tildrakizumab 1:12; 2:9; 6:1-4
tissue grafting techniques 3:3-4
trametinib 2:7
Tremfya® 3:10
tretinoin 2:7
trifarotene 6:10

U
ultrasound 1:3-5

V
vaccine 2:8; 4:5-7
varicella zoster virus 4:5-7
vasculitis 6:10
vitamin D 5:11,14
vitiligo 3:1-6
Voluma® 6:10

W
Wegener’s granulomatosis 6:10

X
Xydalba™ 1:12; 2:7

Y
Yervoy® 1:8-11; 2:7

Z
ZTlido™ 2:9

Purchase Article PDF for $1.99

RELATED ARTICLESMORE FROM THIS ISSUE